Baxter International (BAX) Rising Before The Market Opens

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Baxter International ( BAX) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Baxter International as such a stock due to the following factors:

  • BAX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $280.4 million.
  • BAX traded 13,095 shares today in the pre-market hours as of 7:42 AM.
  • BAX is up 8.5% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BAX with the Ticky from Trade-Ideas. See the FREE profile for BAX NOW at Trade-Ideas

More details on BAX:

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. The stock currently has a dividend yield of 2.9%. BAX has a PE ratio of 18.4. Currently there are 5 analysts that rate Baxter International a buy, no analysts rate it a sell, and 9 rate it a hold.

The average volume for Baxter International has been 3.2 million shares per day over the past 30 days. Baxter International has a market cap of $36.2 billion and is part of the health care sector and health services industry. The stock has a beta of 0.53 and a short float of 2.1% with 3.06 days to cover. Shares are down 1.7% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 3.7%. Since the same quarter one year prior, revenues rose by 16.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • Net operating cash flow has increased to $1,083.00 million or 14.60% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 2.24%.
  • The gross profit margin for BAXTER INTERNATIONAL INC is rather high; currently it is at 55.24%. Regardless of BAX's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.46% trails the industry average.
  • BAXTER INTERNATIONAL INC's earnings per share declined by 33.7% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year. During the past fiscal year, BAXTER INTERNATIONAL INC reported lower earnings of $3.65 versus $4.18 in the prior year. This year, the market expects an improvement in earnings ($5.14 versus $3.65).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

These Stocks Are Ready to Reverse Course

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways